Equities Analysts Offer Predictions for MNPR FY2029 Earnings

Key Points

• HC Wainwright raised Monopar Therapeutics’ FY2029 EPS estimate to $2.44 from $2.41 and maintained a “Buy” rating with a $125 price target. The firm expects FY2030 EPS of $6.77, compared with a current-year consensus loss of $2.82 per share.
• Analyst sentiment is broadly positive, with a consensus “Buy” rating and an average price target of $117.42; three analysts rate the stock Strong Buy and nine rate it Buy.
• MNPR shares opened at $110.41, near their 12-month high of $124.82, while the company reported a quarterly loss of $0.62 per share—slightly better than the expected $0.64 loss.

Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) - Stock analysts at HC Wainwright lifted their FY2029 earnings per share (EPS) estimates for shares of Monopar Therapeutics in a research note issued to investors on Thursday, August 13th. HC Wainwright analyst A. Maldonado now anticipates that the company will earn $2.44 per share for the year, up from their prior estimate of $2.41. HC Wainwright currently has a "Buy" rating and a $125.00 target price on the stock. The consensus estimate for Monopar Therapeutics' current full-year earnings is ($2.82) per share. HC Wainwright also issued estimates for Monopar Therapeutics' FY2030 earnings at $6.77 EPS.

Other equities analysts have also issued research reports about the company. UBS Group set a $125.00 price objective on Monopar Therapeutics in a report on Thursday, July 23rd. Zacks Research raised Monopar Therapeutics from a "hold" rating to a "strong-buy" rating in a research report on Monday, July 13th. Cantor Fitzgerald lowered Monopar Therapeutics from an "overweight" rating to a "neutral" rating and lifted their price target for the stock from $109.00 to $119.00 in a research report on Thursday. Piper Sandler set a $105.00 price objective on Monopar Therapeutics in a research note on Tuesday, June 2nd. Finally, Barclays reissued an "overweight" rating and issued a $128.00 price objective (up from $125.00) on shares of Monopar Therapeutics in a report on Thursday. Three analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $117.42.

Monopar Therapeutics Price Performance

Shares of NASDAQ:MNPR opened at $110.41 on Friday. Monopar Therapeutics has a 12 month low of $29.18 and a 12 month high of $124.82. The firm has a market capitalization of $739.75 million, a P/E ratio of -50.88 and a beta of 1.47. The company's fifty day moving average price is $95.04 and its 200 day moving average price is $71.23.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.64) by $0.02.

Hedge Funds Weigh In On Monopar Therapeutics

Large investors have recently made changes to their positions in the stock. Russell Investments Group Ltd. acquired a new position in Monopar Therapeutics during the third quarter worth about $28,000. BNP Paribas Financial Markets boosted its stake in shares of Monopar Therapeutics by 100.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 696 shares of the company's stock worth $57,000 after acquiring an additional 349 shares in the last quarter. Meeder Asset Management Inc. acquired a new stake in shares of Monopar Therapeutics in the 4th quarter worth approximately $65,000. JPMorgan Chase & Co. grew its holdings in shares of Monopar Therapeutics by 1,821.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company's stock worth $69,000 after acquiring an additional 1,821 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in Monopar Therapeutics in the 2nd quarter valued at approximately $80,000. Hedge funds and other institutional investors own 1.83% of the company's stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company's core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company's pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source